Skip to content

Study · Non-randomized trial · n = 51 · 1999

4 results

[Cerebrolysin and magnesium-B6 in the treatment of side effects of psychotropic drugs].

Panteleeva GP, Bondar' VV, Krasnikova NI, Raiushkin VA

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 1999Cited by 1 (Europe PMC)

PMID11530457 (opens in a new tab)PepBankPUB-11530457
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with psychotropic drug side effects, Cerebrolysin and magnesium-B6 showed equally high efficacy against hyperkinetic symptoms.

    In plain wordsIn patients with psychotropic drug side effects, Cerebrolysin and magnesium-B6 similarly relieved excessive movement symptoms.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedHyperkinetic side effect relief
    Study

    n = 51

    Comparator
    Magnesium-B6
    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    5-10 ml · i.v./dr · 28 daysAs given in this study (human).

    Measurements

    Symptom relief
    59 to 62%
    both drugs

    Source sentences

    Summary
    Both drugs showed equally high efficacy against hyperkinetic and cardiovascular side effects (symptoms relief was in 59-62% and 65-69%, respectively).
    4 context sentences
    Summary · context
    Schizophrenia was diagnosed in 31 patients and endogenous depression in 20 cases.
    Summary · context
    All the patients had extrapyramidal and somato-vegetative side effects of neuroleptics and antidepressive drugs, and were resistant to conventional corrective therapy for at least a period of 3 weeks.
    Summary · context
    In addition to current treatment of both basic disease and adverse effects, cerebrolysin was administered (5-10 ml i.v./dr, during 28 days) and magme B6 (20-30 ml per os during 21 days).
    Summary · context
    51 patients were observed.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with psychotropic drug side effects, Cerebrolysin and magnesium-B6 showed equally high efficacy against cardiovascular symptoms.

    In plain wordsIn patients with psychotropic drug side effects, Cerebrolysin and magnesium-B6 similarly relieved cardiovascular symptoms.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedCardiovascular side effect relief
    Study

    n = 51

    Comparator
    Magnesium-B6
    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    5-10 ml · i.v./dr · 28 daysAs given in this study (human).

    Measurements

    Symptom relief
    65 to 69%
    both drugs

    Source sentences

    Summary
    Both drugs showed equally high efficacy against hyperkinetic and cardiovascular side effects (symptoms relief was in 59-62% and 65-69%, respectively).
    4 context sentences
    Summary · context
    Schizophrenia was diagnosed in 31 patients and endogenous depression in 20 cases.
    Summary · context
    All the patients had extrapyramidal and somato-vegetative side effects of neuroleptics and antidepressive drugs, and were resistant to conventional corrective therapy for at least a period of 3 weeks.
    Summary · context
    In addition to current treatment of both basic disease and adverse effects, cerebrolysin was administered (5-10 ml i.v./dr, during 28 days) and magme B6 (20-30 ml per os during 21 days).
    Summary · context
    51 patients were observed.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with psychotropic drug side effects, Cerebrolysin produced moderate or marked extrapyramidal disorder reduction in 74.4%.

    In plain wordsIn patients with psychotropic drug side effects, Cerebrolysin reduced movement disorders in 74.4%.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseExtrapyramidal disorder response
    Study

    n: not reported in source

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    5-10 ml · i.v./dr · 28 daysAs given in this study (human).

    Measurements

    Moderate or marked reduction
    74.4%
    Cerebrolysin
    Moderate or marked extrapyramidal disorder reduction
    72.2%
    magne B6, treatment end-point, ESRS

    Source sentences

    Summary
    By the treatment end-point either moderate or marked reduction of extrapyramidal disorders (according to ESRS) was observed in 74.4% of patients treated by cerebrolysin and in 72.2% treated by magne B6
    3 context sentences
    Summary · context
    Schizophrenia was diagnosed in 31 patients and endogenous depression in 20 cases.
    Summary · context
    All the patients had extrapyramidal and somato-vegetative side effects of neuroleptics and antidepressive drugs, and were resistant to conventional corrective therapy for at least a period of 3 weeks.
    Summary · context
    In addition to current treatment of both basic disease and adverse effects, cerebrolysin was administered (5-10 ml i.v./dr, during 28 days) and magme B6 (20-30 ml per os during 21 days).
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with psychotropic drug side effects, somato-vegetative adverse effects decreased in 85.8% with Cerebrolysin.

    In plain wordsIn patients with psychotropic drug side effects, Cerebrolysin reduced somatic and autonomic symptoms in 85.8%.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseSomato-vegetative adverse effect response
    Study

    n: not reported in source

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    5-10 ml · i.v./dr · 28 daysAs given in this study (human).

    Measurements

    Symptom reduction
    85.8%
    Cerebrolysin
    Somato-vegetative adverse effect reduction
    83.8%
    magne B6, treatment end-point, SARS

    Source sentences

    Summary
    somato-vegetative adverse effects reduced (by SARS) in 85.8% and in 83.8% respectively.
    Summary
    By the treatment end-point either moderate or marked reduction of extrapyramidal disorders (according to ESRS) was observed in 74.4% of patients treated by cerebrolysin and in 72.2% treated by magne B6
    3 context sentences
    Summary · context
    Schizophrenia was diagnosed in 31 patients and endogenous depression in 20 cases.
    Summary · context
    All the patients had extrapyramidal and somato-vegetative side effects of neuroleptics and antidepressive drugs, and were resistant to conventional corrective therapy for at least a period of 3 weeks.
    Summary · context
    In addition to current treatment of both basic disease and adverse effects, cerebrolysin was administered (5-10 ml i.v./dr, during 28 days) and magme B6 (20-30 ml per os during 21 days).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.